FDA tentative approval vs. final approval: what generic peptide status means

01

Tentative approval is a defined ANDA status

FDA's Drugs@FDA glossary explains that when a generic product is ready for approval before relevant patents or exclusivities for the reference listed drug expire, FDA can issue a tentative approval letter. The letter describes the application-specific circumstances. FDA delays final approval until the legal barrier is resolved.

Tentative approval reflects a substantive regulatory review at that point, but it is not permission to market the product in the United States. FDA's generic-program dashboard likewise states that a tentative approval letter does not allow marketing. Consumer-facing articles should never shorten “tentatively approved” to “approved generic.”

The status applies to a specific ANDA applicant, active ingredient, strength, dosage form, route, and proposed labeling. It does not attach to every manufacturer or product using the ingredient name and does not validate a compounded preparation or research product.

02

Why patents and exclusivities can delay final approval

Brand-name drugs can have patents and statutory marketing exclusivities that affect when a generic can receive final approval. FDA must apply the governing patent certifications, exclusivity periods, court outcomes, and any relevant statutory stay. These mechanisms are legal barriers to final approval rather than evidence that a tentatively approved product may already be sold.

A tentative approval letter is the best source for the stated circumstance, but public availability and wording vary. Do not calculate a launch date from a patent table alone. Litigation, pediatric exclusivity, 180-day generic exclusivity, application updates, manufacturing readiness, and later FDA review can affect timing.

A generic may use labeling that omits a protected use when legally and scientifically permissible, sometimes called a carve-out. That does not make every use of the reference drug available to the generic, and the final approved label should be checked rather than inferred from the brand's full indication list.

03

What changes at final approval

Final approval is a later FDA action authorizing marketing of the identified generic under the approved conditions. FDA's Orange Book preface states that a tentatively approved product is not an approved drug product and is not included in the approved-drug lists. After a subsequent final approval action, FDA lists the product and approval date in the appropriate record.

Final approval is not necessarily automatic when an expected patent or exclusivity date arrives. FDA may need updated information, facilities and manufacturing controls must remain acceptable, and the application must satisfy requirements at the time of final action. Use the actual FDA approval letter and database date, not a sponsor projection.

Even after final approval, commercial availability can lag. FDA's first-generic materials caution that an approved product may not be available on the approval date. Approval status, launch status, pharmacy inventory, insurance coverage, and patient suitability are separate questions.

04

Verify the status in Drugs@FDA and the Orange Book

Search Drugs@FDA's Drug Approval Reports by Month for tentative approvals using the active ingredient, applicant, and ANDA number. FDA says the reports are updated daily. Open the application record and look for a later final approval action rather than relying on an old news release or company pipeline page.

Then search the Orange Book for the exact active ingredient, strength, dosage form, route, applicant, and application number. A tentatively approved product should not appear as an approved product merely because the reference listed drug or another generic appears. Once final approval occurs, confirm the product listing and current label.

Preserve the access date because status can change. If the application remains tentative, state that clearly and avoid predicting approval or launch. If a current final approval appears, update the article and link the action rather than leaving stale tentative language in place.

• →Active ingredient and reference product
• →ANDA number and applicant
• →Tentative approval date and letter
• →Later final approval action
• →Orange Book product listing
• →Current label and actual availability

05

Separate look-alike generic categories

An FDA-approved generic normally has an approved ANDA. An authorized generic is marketed under the brand product's NDA rather than its own ANDA and appears on FDA's separate authorized-generic list. A compounded drug is prepared under a compounding framework and is not FDA-approved. A product approved by a regulator outside the United States does not thereby have FDA approval.

A tentative ANDA also does not establish an approved substitution or therapeutic-equivalence code. Therapeutic-equivalence evaluations concern approved products in the Orange Book. A provider or pharmacy should identify the exact dispensed product and application rather than claiming equivalence from ingredient name or tentative status.

For peptide drugs, complex manufacturing, impurities, immunogenicity, and product characterization can make generic review scientifically demanding. Tentative status is not a shortcut around those standards, but it also is not a consumer quality ranking or treatment recommendation.

06

Marketing claims and warning signs

Question “FDA approved pending patent expiration,” “pre-approved generic,” “same FDA file,” and “approved but not launched” unless the speaker distinguishes tentative from final action and links the exact record. Also question a U.S. seller offering a supposedly tentatively approved injectable as though the status authorizes sales.

Do not assume that a tentatively approved semaglutide or other peptide application—if one exists—makes compounded versions FDA-approved generics. The ANDA record belongs to the named applicant and product. A compounding pharmacy cannot borrow its status, and a clinic cannot convert a different formulation into an approved generic through marketing language.

Regulatory research can clarify status but cannot determine whether a medication is appropriate for an individual. Treatment and substitution questions should go to an appropriately licensed prescriber and pharmacist using the exact current product and label.